KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Elanco Animal Health (ELAN) Research & Development (2017 - 2025)

Historic Research & Development for Elanco Animal Health (ELAN) over the last 9 years, with Q3 2025 value amounting to $89.0 million.

  • Elanco Animal Health's Research & Development rose 229.89% to $89.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $356.0 million, marking a year-over-year increase of 409.36%. This contributed to the annual value of $344.0 million for FY2024, which is 519.88% up from last year.
  • According to the latest figures from Q3 2025, Elanco Animal Health's Research & Development is $89.0 million, which was up 229.89% from $92.0 million recorded in Q2 2025.
  • In the past 5 years, Elanco Animal Health's Research & Development registered a high of $94.0 million during Q2 2021, and its lowest value of $78.0 million during Q3 2022.
  • Moreover, its 5-year median value for Research & Development was $87.0 million (2024), whereas its average is $86.1 million.
  • Within the past 5 years, the most significant YoY rise in Elanco Animal Health's Research & Development was 5932.2% (2021), while the steepest drop was 2000.0% (2021).
  • Elanco Animal Health's Research & Development (Quarter) stood at $92.0 million in 2021, then dropped by 13.04% to $80.0 million in 2022, then fell by 1.25% to $79.0 million in 2023, then rose by 2.53% to $81.0 million in 2024, then rose by 9.88% to $89.0 million in 2025.
  • Its last three reported values are $89.0 million in Q3 2025, $92.0 million for Q2 2025, and $94.0 million during Q1 2025.